Jani Leinonen, Renowned Finnish Artist, Is Releasing His First NFT on Swappable
Jani Leinonen, the renowned Finnish artist, will offer a 3 day NFT auction of his one-of-one animated artwork titled ‘Things You Own’, on Swappable, until Friday, August 27th at 10am PST. Swappable is a new interface for non-fungible tokens (NFTs) powered by TrustSwap.
Leinonen will be participating in an AMA Ask-Me-Anything event, offering the opportunity for the community to ask him questions.
Leinonen’s first NFT is supported by Stalla Madulain, the renowned Swiss art gallery dating back to 1488 and one of his most ardent supporters. As well as Switzerland-based international fine art logistics and infrastructure provider Haas & Company AG, a reputed partner of art collectors, galleries, museums, and art fairs worldwide which provides custody services for tokenized physical assets.
Swappable, powered by TrustSwap, will create a creative place for artists to sell their artworks and for users to find and collect artworks and digital collectibles. Jeff Kirdeikis, CEO of TrustSwap, mentions: “We are extremely excited to be working with such a renowned artist, we’ve created a platform that reduces the entrance barrier to the NFT space to support creators like Jani Leinonen.”
Leinonen is known for his provocative, yet playful works, criticizing capitalism and consumerism. In 2016, Leinonen was awarded the Finland Prize by the Ministry of Education and Culture, which is given in recognition of a significant career in arts. His work can be found in museums, and in private and public collections on every continent. He is currently exhibiting in Serlachius Museum with the street artist Banksy, and Salo Art Museum. The Five-star hotel Dolder Grand in Zurich has 12 of Leinonen’s works on permanent display. You can find out more about Leinonen on his website.
Jani Leinonen, on his NFT artwork ‘Things you own’: “Have we become more consumers than citizens? Our values, our political views, our emotions, traumas, and our dreams, are revealed by this sacred shopping cart. When we take a look at this portrait of us, how much do we recognize as our own? Will there truly be a new better world displacing the established and old, or will we forever be owned by the things we own?”
The team behind Swappable boasts that the Jani Leinonen collaboration is just the beginning, with many interesting collaborations to be revealed soon.
Swappable is the latest offering from TrustSwap
TrustSwap is a blockchain venture that offers smart contact services and innovative solutions for decentralized finance (DeFi) and commerce to help the crypto community transact with integrity, and accountability. TrustSwap solves problems in the DeFi space connected to tracking and buying crypto with ‘The Crypto App’, split payments, subscriptions, escrow, minting, token locks, and fundraising. TrustSwap is building foundational layers in the rapidly-emerging decentralized finance and commerce landscape with services like The Crypto App, SmartLocks, Mint, Launchpad, and Swappable’s NFT interface. Visit www.trustswap.org for information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210824005826/en/
Contact information
Howard Pearce
howard@trustswap.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 03:09:00 EEST | Press release
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio ha
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom